Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Botox maker Allergan’s 2018 revenue forecast misses estimates, shares drop

Allergan Plc forecast 2019 revenue below expectations on looming competition for some of the company’s top drugs, and shelved plans to sell the women’s health business.

Read More »

Pfizer forecasts 2019 revenue below Wall Street targets

Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.

Read More »

Biogen beats Q4 2018 estimates on sales of multiple sclerosis drugs

Biogen Inc. beat analysts’ estimates for fourth-quarter profit and revenue, buoyed by higher sales of the company’s top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.

Read More »

Apple Watch, using Aetna client data, wants to help you be healthy

CVS Health Corp.’s health insurer Aetna is working with Apple Inc. on a new health app for Apple Watches that uses an individual’s medical history to set personalized health goals.

Read More »

SQI Diagnostics’ Partner Launches Two New Direct-to-Consumer Tests

SQI Diagnostics Inc. announced two new product launches within the imaware family of at-home tests by its partner, Microdrop.

Read More »

Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland

Cerecor Inc. announced that the company moved its U.S. corporate offices to Rockville, Maryland after previously being based in Baltimore.

Read More »

Insys founder, former executives face opioid kickback scheme trial

The one-time billionaire founder of Insys Therapeutics Inc. and four other former executives and managers of the opioid drugmaker will face trial over charges they conspired to pay doctors bribes to prescribe patients an addictive fentanyl spray to boost sales.

Read More »

Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.

Read More »

AbbVie’s 2018: Revenues Up, Earnings Down

AbbVie reported a loss of $1.83 billion for the fourth quarter of 2018. Overall revenues were up for full-year 2018, however, hitting $32.75 billion compared to $28.2 billion in 2017.

Read More »

Indivior temporarily stops rival Alvogen’s generic launch

Indivior said a U.S. district court had granted the British drugmaker a temporary restraining order, stopping rival Alvogen from launching cut-price versions of the company’s blockbuster opioid addiction treatment.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom